ArticleAlzheimer's research & therapy2026
Interactive effects of telomere length and genetic variants on Alzheimer disease risk across multiple ancestral populations.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
15 authors.
Funding
Abstract
backgroundTelomere length (TL), a biomarker of biological aging, but its association with Alzheimer’s disease (AD) remains unclear.
methodsWe estimated TL in whole-genome sequencing data from 35,014 Alzheimer’s Disease Sequencing Project participants using TelSeq, which after quality control yielded a dataset including 6,973 persons of European ancestry (EA), 4,188 African Americans (AA), 4,005 Caribbean Hispanics (CH), and 4,170 Native American Hispanics (NAH). TL was log-transformed, adjusted for age and blood cell counts, and z-scaled. Scaled TL was dichotomized into long (TL > 0) and short (TL ≤ 0) groups. An AD GWAS for the interaction of TL with variants having a minor allele count > 20 was performed in each ancestry group using logistic regression models including SNP and TL main effects and a SNP × TL interaction term.
resultsAD risk was associated with shorter TL (β = -0.48, P < 2 × 10–16). Longer and shorter TL were associated with dosages of APOE ε2 (P = 3.40 × 10–4) and ε4 (P = 7.05 × 10–3), respectively. In the EA group, genome-wide significant (GWS) TL × SNP interactions were identified for variants in SEMA6A (P = 1.42 × 10–8) and LOC105378654 (P = 4.17 × 10–8), between IL15 and INPP4B (P = 1.77 × 10–8) and upstream of RP11-2N5.2 (P = 4.60 × 10–8). In the NAH group, GWS interactions were observed with an intronic variant in BSN (P = 3.26 × 10–8) and missense variant in MST1 (P = 3.26 × 10–8). In the total sample, interactions with variants between CTD-2160D9.1 and EEF1A1P20 (P < 1.19 × 10–8), in TBC1D22A (P = 1.06 × 10–8) and in PLK1 (P = 3.28 × 10–8) were GWS.
conclusionWe identified variants that significantly impact AD risk through their interaction with TL, suggesting that TL maintenance pathways may be central to AD pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.